Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
6
ACTU Quote, Financials, Valuation and Earnings
Last price:
$3.84
Seasonality move
:
37.94%
Day range:
$3.74 - $4.44
52-week range:
$3.72 - $11.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
7.95x
Volume:
24K
Avg. volume:
51.1K
1-year change:
-46.03%
Market cap:
$86.9M
Revenue:
--
EPS (TTM):
-$1.21
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ACTU
Actuate Therapeutics, Inc.
|
-- | -$0.25 | -- | -22.84% | $25.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.80 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$230.8M | -$0.37 | -87.74% | -73.49% | $81.36 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ACTU
Actuate Therapeutics, Inc.
|
$3.74 | $25.00 | $86.9M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.56 | $31.80 | $4.2B | 10.73x | $0.00 | 0% | 3.89x |
|
AGEN
Agenus, Inc.
|
$3.33 | $12.33 | $120.4M | -- | $0.00 | 0% | 0.84x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$332.92 | $457.00 | $44.2B | 147.50x | $0.00 | 0% | 11.97x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$63.27 | $81.36 | $8.9B | 41.13x | $0.00 | 0% | 7.97x |
|
SVRA
Savara, Inc.
|
$6.02 | $10.81 | $1.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ACTU
Actuate Therapeutics, Inc.
|
3.57% | -0.316 | 0.26% | 2.66x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
AGEN
Agenus, Inc.
|
510.35% | 3.128 | 285.06% | 0.03x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 0.880 | 5.64% | 2.51x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
54.75% | 3.931 | 7.54% | 3.27x |
|
SVRA
Savara, Inc.
|
24.02% | -2.483 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ACTU
Actuate Therapeutics, Inc.
|
-- | -$5.5M | -1128.92% | -1392.96% | -- | -$6.5M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$257.6M | $40.8M | 19.23% | 50.21% | 15.46% | $11.3M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Actuate Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ACTU or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Actuate Therapeutics, Inc.'s net margin of 96.33%. Actuate Therapeutics, Inc.'s return on equity of -1392.96% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital ACTUActuate Therapeutics, Inc.-- -$0.25 $11.3M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About ACTU or ACAD?
Actuate Therapeutics, Inc. has a consensus price target of $25.00, signalling upside risk potential of 569.25%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.80 which suggests that it could grow by 29.48%. Given that Actuate Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Actuate Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACTUActuate Therapeutics, Inc.4 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is ACTU or ACAD More Risky?
Actuate Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock ACTU or ACAD?
Actuate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actuate Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACTU or ACAD?
Actuate Therapeutics, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Actuate Therapeutics, Inc.'s net income of -$5.4M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Actuate Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 10.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actuate Therapeutics, Inc. is -- versus 3.89x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACTUActuate Therapeutics, Inc.-- -- -- -$5.4M ACADACADIA Pharmaceuticals, Inc.3.89x 10.73x $284M $273.6M
-
Which has Higher Returns ACTU or AGEN?
Agenus, Inc. has a net margin of -- compared to Actuate Therapeutics, Inc.'s net margin of -116.82%. Actuate Therapeutics, Inc.'s return on equity of -1392.96% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ACTUActuate Therapeutics, Inc.-- -$0.25 $11.3M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About ACTU or AGEN?
Actuate Therapeutics, Inc. has a consensus price target of $25.00, signalling upside risk potential of 569.25%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 270.37%. Given that Actuate Therapeutics, Inc. has higher upside potential than Agenus, Inc., analysts believe Actuate Therapeutics, Inc. is more attractive than Agenus, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACTUActuate Therapeutics, Inc.4 0 0 AGENAgenus, Inc.2 1 0 -
Is ACTU or AGEN More Risky?
Actuate Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.567, suggesting its more volatile than the S&P 500 by 56.664%.
-
Which is a Better Dividend Stock ACTU or AGEN?
Actuate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actuate Therapeutics, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACTU or AGEN?
Actuate Therapeutics, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. Actuate Therapeutics, Inc.'s net income of -$5.4M is lower than Agenus, Inc.'s net income of $63.9M. Notably, Actuate Therapeutics, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actuate Therapeutics, Inc. is -- versus 0.84x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACTUActuate Therapeutics, Inc.-- -- -- -$5.4M AGENAgenus, Inc.0.84x -- $30.2M $63.9M
-
Which has Higher Returns ACTU or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Actuate Therapeutics, Inc.'s net margin of 16.99%. Actuate Therapeutics, Inc.'s return on equity of -1392.96% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital ACTUActuate Therapeutics, Inc.-- -$0.25 $11.3M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About ACTU or ALNY?
Actuate Therapeutics, Inc. has a consensus price target of $25.00, signalling upside risk potential of 569.25%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.27%. Given that Actuate Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Actuate Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACTUActuate Therapeutics, Inc.4 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is ACTU or ALNY More Risky?
Actuate Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.
-
Which is a Better Dividend Stock ACTU or ALNY?
Actuate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actuate Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACTU or ALNY?
Actuate Therapeutics, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Actuate Therapeutics, Inc.'s net income of -$5.4M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Actuate Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 147.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actuate Therapeutics, Inc. is -- versus 11.97x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACTUActuate Therapeutics, Inc.-- -- -- -$5.4M ALNYAlnylam Pharmaceuticals, Inc.11.97x 147.50x $1.1B $186.4M
-
Which has Higher Returns ACTU or ARWR?
Arrowhead Pharmaceuticals, Inc. has a net margin of -- compared to Actuate Therapeutics, Inc.'s net margin of 10.7%. Actuate Therapeutics, Inc.'s return on equity of -1392.96% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 50.21%.
Company Gross Margin Earnings Per Share Invested Capital ACTUActuate Therapeutics, Inc.-- -$0.25 $11.3M ARWRArrowhead Pharmaceuticals, Inc.97.58% $0.22 $1.3B -
What do Analysts Say About ACTU or ARWR?
Actuate Therapeutics, Inc. has a consensus price target of $25.00, signalling upside risk potential of 569.25%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $81.36 which suggests that it could grow by 28.6%. Given that Actuate Therapeutics, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Actuate Therapeutics, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACTUActuate Therapeutics, Inc.4 0 0 ARWRArrowhead Pharmaceuticals, Inc.7 3 0 -
Is ACTU or ARWR More Risky?
Actuate Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.227, suggesting its more volatile than the S&P 500 by 22.681%.
-
Which is a Better Dividend Stock ACTU or ARWR?
Actuate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actuate Therapeutics, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACTU or ARWR?
Actuate Therapeutics, Inc. quarterly revenues are --, which are smaller than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $264M. Actuate Therapeutics, Inc.'s net income of -$5.4M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $28.2M. Notably, Actuate Therapeutics, Inc.'s price-to-earnings ratio is -- while Arrowhead Pharmaceuticals, Inc.'s PE ratio is 41.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actuate Therapeutics, Inc. is -- versus 7.97x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACTUActuate Therapeutics, Inc.-- -- -- -$5.4M ARWRArrowhead Pharmaceuticals, Inc.7.97x 41.13x $264M $28.2M
-
Which has Higher Returns ACTU or SVRA?
Savara, Inc. has a net margin of -- compared to Actuate Therapeutics, Inc.'s net margin of --. Actuate Therapeutics, Inc.'s return on equity of -1392.96% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital ACTUActuate Therapeutics, Inc.-- -$0.25 $11.3M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About ACTU or SVRA?
Actuate Therapeutics, Inc. has a consensus price target of $25.00, signalling upside risk potential of 569.25%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 79.61%. Given that Actuate Therapeutics, Inc. has higher upside potential than Savara, Inc., analysts believe Actuate Therapeutics, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACTUActuate Therapeutics, Inc.4 0 0 SVRASavara, Inc.6 0 0 -
Is ACTU or SVRA More Risky?
Actuate Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.931%.
-
Which is a Better Dividend Stock ACTU or SVRA?
Actuate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Actuate Therapeutics, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACTU or SVRA?
Actuate Therapeutics, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Actuate Therapeutics, Inc.'s net income of -$5.4M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Actuate Therapeutics, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Actuate Therapeutics, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACTUActuate Therapeutics, Inc.-- -- -- -$5.4M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Mar 2
Applied Optoelectronics, Inc. [AAOI] is up 21.71% over the past day.
Buy
90
BNAI alert for Mar 2
Brand Engagement Network, Inc. [BNAI] is up 2.44% over the past day.
Sell
36
WLDN alert for Mar 2
Willdan Group, Inc. [WLDN] is down 1.93% over the past day.
